ICON Public (NASDAQ:ICLR) Given New $265.00 Price Target at JPMorgan Chase & Co.

ICON Public (NASDAQ:ICLR - Free Report) had its target price decreased by JPMorgan Chase & Co. from $280.00 to $265.00 in a research report report published on Monday morning,Benzinga reports. JPMorgan Chase & Co. currently has an overweight rating on the medical research company's stock.

A number of other research analysts have also weighed in on the stock. Citigroup decreased their target price on shares of ICON Public from $300.00 to $290.00 and set a "buy" rating on the stock in a research note on Monday, January 6th. William Blair reaffirmed an "outperform" rating on shares of ICON Public in a research report on Tuesday, January 14th. The Goldman Sachs Group cut their target price on ICON Public from $370.00 to $280.00 and set a "buy" rating on the stock in a research report on Friday, October 25th. Barclays cut their target price on ICON Public from $330.00 to $275.00 and set an "overweight" rating on the stock in a research report on Friday, October 25th. Finally, Baird R W lowered ICON Public from a "strong-buy" rating to a "hold" rating in a research report on Thursday, October 24th. Four investment analysts have rated the stock with a hold rating, eleven have assigned a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat, ICON Public has an average rating of "Moderate Buy" and a consensus price target of $285.75.

ICON Public Price Performance

ICLR stock traded up $4.13 during trading on Monday, hitting $197.40. The stock had a trading volume of 265,632 shares, compared to its average volume of 915,630. The company has a debt-to-equity ratio of 0.35, a current ratio of 1.34 and a quick ratio of 1.34. ICON Public has a twelve month low of $183.38 and a twelve month high of $347.72. The stock has a market capitalization of $16.29 billion, a P/E ratio of 21.99, a PEG ratio of 1.79 and a beta of 1.19. The company's 50-day moving average price is $208.53 and its two-hundred day moving average price is $256.54.

Institutional Trading of ICON Public

Several large investors have recently modified their holdings of ICLR. Kornitzer Capital Management Inc. KS raised its stake in ICON Public by 40.6% during the fourth quarter. Kornitzer Capital Management Inc. KS now owns 97,102 shares of the medical research company's stock worth $20,363,000 after purchasing an additional 28,050 shares during the period. Foyston Gordon & Payne Inc bought a new stake in shares of ICON Public during the 3rd quarter worth about $11,672,000. Icon Wealth Advisors LLC raised its position in shares of ICON Public by 861.1% during the 3rd quarter. Icon Wealth Advisors LLC now owns 13,215 shares of the medical research company's stock worth $3,797,000 after buying an additional 11,840 shares in the last quarter. Entropy Technologies LP lifted its position in shares of ICON Public by 472.2% in the 4th quarter. Entropy Technologies LP now owns 6,174 shares of the medical research company's stock valued at $1,295,000 after acquiring an additional 5,095 shares in the last quarter. Finally, Whittier Trust Co. increased its stake in ICON Public by 12.3% in the 3rd quarter. Whittier Trust Co. now owns 4,020 shares of the medical research company's stock valued at $1,155,000 after buying an additional 441 shares during the period. 95.61% of the stock is currently owned by institutional investors and hedge funds.

About ICON Public

ICON Public Limited Company, a clinical research organization, provides outsourced development and commercialization services in Ireland, rest of Europe, the United States, and internationally. The company specializes in the strategic development, management, and analysis of programs that support various stages of the clinical development process from compound selection to Phase I-IV clinical studies.